Samay Shivshankar

Mr. Samay Shivshankar

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
ARAleix Ribas-Latre
Aleix Ribas-Latre
RSRafael Bravo Santos
Rafael Bravo Santos
BFBaharan Fekry
Baharan Fekry
YTYomna M. Tamim
Yomna M. Tamim
SSSamay Shivshankar
Samay Shivshankar
KEKristin L. eckel-mahan
Kristin L. eckel-mahan
Hyperplastic expansion of white adipose tissue (WAT) relies in part on the proliferation of adipocyte precursor cells residing in the stromal vascular cell fraction (SVF) of WAT. This study reveals a circadian clock- and feeding-induced diurnal pattern of cell proliferation in the SVF of visceral and subcutaneous WAT in vivo, with higher proliferation of visceral adipocyte progenitor cells subsequent to feeding in lean mice. Fasting or loss of rhythmic feeding eliminates this diurnal proliferation, while high fat feeding or genetic disruption of the molecular circadian clock modifies the temporal expression of proliferation genes and impinges on diurnal SVF proliferation in eWAT. Surprisingly, high fat diet reversal, sufficient to reverse elevated SVF proliferation in eWAT, was insufficient in restoring diurnal patterns of SVF proliferation, suggesting that high fat diet induces a sustained disruption of the adipose circadian clock. In conclusion, the circadian clock and feeding simultaneously impart dynamic, regulatory control of adipocyte progenitor proliferation, which may be a critical determinant of adipose tissue expansion and health over time.

24 May 2018 in International Journal of Obesity
Verified
Journal Article
Open access
PDF file
ARAleix Ribas-Latre
Aleix Ribas-Latre
BFBaharan Fekry
Baharan Fekry
CKChristopher Kwok
Christopher Kwok
CBCorrine Baumgartner
Corrine Baumgartner
SSSamay Shivshankar
Samay Shivshankar
KEKristin L. eckel-mahan
Kristin L. eckel-mahan
Nutrient challenge in the form of a high fat (HF) diet causes a reversible reprogramming of the hepatic circadian clock. This depends in part on changes in the recruitment of the circadian transcription factor BMAL1 to genome targets, though the causes and extent of disruption to hepatic and extra-hepatic BMAL1 are unknown. The objective of the study was to determine whether HF diet-induced alterations in BMAL1 function occur across insulin-resistant tissues and whether this could be reversed by restoring whole body insulin sensitivity. BMAL1 subcellular localization and target recruitment was analyzed in several metabolically active peripheral tissues, including liver, muscle, and adipose tissue under conditions of diet-induced obesity. Animals made obese with HF diet were subsequently treated with rosiglitazone to determine whether resensitizing insulin-resistant tissues to insulin restored hepatic and extra-hepatic BMAL1 function. These data reveal that both hepatic and extra-hepatic BMAL1 activity are altered under conditions of obesity and insulin resistance. Restoring whole body insulin sensitivity by treatment with the antidiabetic drug rosiglitazone is sufficient to restore changes in HF diet-induced BMAL1 recruitment and activity in several tissues. This study reveals that a key mechanism by which HF diet interferes with clock function in peripheral tissues is via the development of insulin resistance.

20 July 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
ARAleix Ribas-Latre
Aleix Ribas-Latre
RSRafael Bravo Santos
Rafael Bravo Santos
BFBaharan Fekry
Baharan Fekry
YTYomna M. Tamim
Yomna M. Tamim
SSSamay Shivshankar
Samay Shivshankar
KEKristin L. eckel-mahan
Kristin L. eckel-mahan

Verified
Journal Article
Open access
PDF file
PBPinaki Bhattacharjee
Pinaki Bhattacharjee
PVPaul Devan Volesky
Paul Devan Volesky
SSSamay Shivshankar
Samay Shivshankar
HPHenry Puhl
Henry Puhl
MIMalliga R. Iyer
Malliga R. Iyer
The G-protein-coupled receptor cannabinoid receptor 2 (CB2R) initiates a key signaling pathway in mammalian physiology and pathophysiology. CB2R signaling holds significant therapeutic potential in ameliorating many pathologies, particularly in inflammatory conditions, neurodegenerative disorders, fibroproliferative and ocular diseases. CB2 modulators have been studied for their anti-inflammatory and tissue protective effects in preclinical animal models of cardiovascular, gastrointestinal, liver, kidney, lung and neurodegenerative disorders with numerous compounds undergoing clinical evaluation. Existing ligands can be classified as endocannabinoids, cannabinoid-like natural products and synthetic CB2R ligands. A genetically encoded G-protein-coupled receptor activation-based (GRAB) sensor for CB1R—GRABeCB2.0 was developed recently. This current study extends the sensor’s development to allow for a GPCR activation-based sensor for CB2R. The sensor, GRAB-CB2, will facilitate the evaluation of pharmacological characteristics and responses of various functionally selective and indiscriminate cannabinoid ligands acting on CB2.